Document is current
Any future updates will be listed below
-
Authors
Vu, Mai Ha https://orcid.org/0000-0002-9702-226X
Robert, Philippe A. https://orcid.org/0000-0003-1345-5015
Akbar, Rahmad https://orcid.org/0000-0002-6692-0876
Swiatczak, Bartlomiej https://orcid.org/0000-0001-6767-3064
Sandve, Geir Kjetil https://orcid.org/0000-0002-4959-1409
Haug, Dag Trygve Truslew https://orcid.org/0000-0001-5275-8073
Greiff, Victor https://orcid.org/0000-0003-2622-5032
-
Funding
Funding for this research was provided by:
University of Oslo | Livsvitenskap, Universitetet i Oslo
Norges Forskningsråd (311341)
Norges Forskningsråd (300740)
Norges Forskningsråd (331890)
Norges Forskningsråd (311341)
Stiftelsen Kristian Gerhard Jebsen
Leona M. and Harry B. Helmsley Charitable Trust (2019PG-T1D011)
EC | Horizon 2020 Framework Programme (825821)
Kreftforeningen (215817)
- License Information
-
More Information
Article History
Received: 29 September 2022
Accepted: 13 May 2024
First Online: 14 June 2024
Competing interests
: V.G. declares advisory board positions in aiNET GmbH, Enpicom B.V, Specifica Inc, Adaptyv Biosystems, EVQLV, Omniscope, Diagonal Therapeutics and Absci. V.G. is a consultant for Roche/Genentech, immunai, Proteinea and LabGenius.
